Table 1

Change in RAMRIS (Rheumatoid Arthritis Magnetic Resonance Imaging Studies) synovitis, osteitis and erosion scores in eight recent randomised controlled trials3

DEN (denosumab)TASKi (fostamatinib)OPTIMA (adalimumab)ASSET (abatacept)SCORE (rituximab)GO-BEFORE (golimumab)GO-FORWARD (golimumab)ACT-RAY (tocilizumab)
MTX-IRBiological agent-IRMTX-naiveMTX-IRMTX-IRMTX-naiveMTX-IRMTX-IR
PBORxPBORxPBORxPBORxPBORxPBORxPBORxRxRx
n6766731463227232563608215972962929
Weeks2424121226261616122412241224122412241224212
SynovitisNANA0.4−0.5*−2.0−3.6*0.5−0.4−0.20.2−1.2*−1.8*0.1−1.0−1.9*−2.5*−0.2−0.4−1.8*−1.9*−0.9*−1.9*
OsteitisNANA1.2−0.20−4.0*1.5−1.9−0.10.1−1.9*−2.9*0.6−0.3−1.8*−2.3*0.20.7−2.0*−1.7*−0.7−5.1*
Erosion1.80.1*0.90.81.4−0.8*1.00.50.31.60.10.2*0.2−0.2−0.4*−0.4*−0.8−0.5−1.0−0.90.2−0.0
  • *p<0.05.

  • IR, inadequate responder; MTX, methotrexate; NA, not assessed; PBO, placebo arm; Rx, active-treatment arm.